Literature DB >> 694479

[Antibodies against nicotine-like acetylcholine receptors of central nervous system and muscles in epileptics with IgA deficiency].

A Fontana, B W Fulpius, S Cuénoud.   

Abstract

Anti-muscle nicotinic acetylcholine receptor (nAR) antibodies were sought in epileptic patients without clinical signs of myasthenia gravis. Low titers of such antibodies were found in 3 cases characterized by primary generalized seizures, IgA deficiency and HLA A1 and B8 antigens. These three patients also had anti-brain nAR antibodies. In the serum of one patient with myasthenia gravis, anti-brain nAR antibodies were also detected. The titer was low despite a high titer of anti-muscle nAR antibodies. This may reflect the fact that the immune reaction in the three epileptic patients is primarily directed against the brain nAR.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 694479

Source DB:  PubMed          Journal:  Schweiz Med Wochenschr        ISSN: 0036-7672


  5 in total

1.  Interactions of antinicotinic acetylcholine receptor antibodies with rat brain and muscle antigenic determinants.

Authors:  R J Lukas
Journal:  Cell Mol Neurobiol       Date:  1986-09       Impact factor: 5.046

2.  Multireactive pattern of serum autoantibodies in asymptomatic individuals with immunoglobulin A deficiency.

Authors:  N Barka; G Q Shen; Y Shoenfeld; I J Alosachie; M E Gershwin; H Reyes; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-07

3.  Immunodeficiency in epilepsy: a new view.

Authors:  A Fontana; P J Grob
Journal:  J Neurol       Date:  1979-01-05       Impact factor: 4.849

4.  Treatment of idiopathic West and Lennox-Gastaut syndromes by intravenous administration of human polyvalent immunoglobulins.

Authors:  K van Rijckevorsel-Harmant; M Delire; M Rucquoy-Ponsar
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1986

5.  Acetylcholine receptor-reactive T and B cells in myasthenia gravis and controls.

Authors:  H Link; O Olsson; J Sun; W Z Wang; G Andersson; H P Ekre; T Brenner; O Abramsky; T Olsson
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.